BioPharmSignal logoBioPharmSignal

Biotech News

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

Corvus Pharmaceuticals (CRVS)Corvus PharmaceuticalsConference / presentation

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat

Related news

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

LEGNLegend Biotech Corporation2026-09-01 12:00 EST

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

CRVSCorvus Pharmaceuticals2026-08-27 11:30 EST

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

CRVSCorvus Pharmaceuticals2026-08-06 20:01 EST

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

View all latest news

Corvus Pharmaceuticals

ITK Inhibition Corvus Pharmaceuticals develops therapies based on inhibition of interleukin-2-inducible T-cell kinase, or ITK. The approach is intended to rebalance immune-cell activity in inflammatory diseases and cancer. Soquelitinib Soquelitinib is an oral, selective ITK inhibitor. Its lead immunology program is a Phase 2 study in...

Recent company news

CRVSCorvus Pharmaceuticals2026-09-03 12:30 EST

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

CRVSCorvus Pharmaceuticals2026-08-27 11:30 EST

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

CRVSCorvus Pharmaceuticals2026-08-06 20:01 EST

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

CRVSCorvus Pharmaceuticals2026-07-30 20:01 EST

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

CRVSCorvus Pharmaceuticals2026-06-09 11:30 EST

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Stock data

Close
12.55 USD
Market cap
983.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States